FDA Approves Rusfertide, First-in-Class Hepcidin Mimetic for Polycythemia Vera

Regulatory Approvals — FDA Approves Rusfertide, First-in-Class Hepcidin Mimetic for Polycythemia Vera  Oncology Nursing News

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. September 1, 2026.

By